Well the experts are very exited by the data and what they saw , that’s is enough for me when u have no treatment options. The fda reconfirmed this by allowing p3 and last time I checked they don’t just hand out rubber stamps for p3.
The problem is there is little in the pipeline to treat these conditions so I doubt pharma would let Neu pass just to wait and see if a competitor comes up with something better
First mover advantage here will be huge
Well the experts are very exited by the data and what they saw ,...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.14 |
Change
-1.000(4.52%) |
Mkt cap ! $2.716B | |||
| Open | High | Low | Value | Volume |
| $22.06 | $22.11 | $21.07 | $3.777M | 175.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 172 | $21.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.16 | 116 | 8 |
View Market Depth
| Last trade - 12.04pm 18/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |